BioCentury | Oct 26, 2018
Emerging Company Profile

Karius: Blood will tell

...Test to diagnose infections in patients with chemotherapy-induced neutropenia in Nohla’s Phase IIb trial of dilanubicel (NLA101)...
BioCentury | Jul 13, 2018
Financial News

Nohla adds $11M to series B

...the round in May (see “Arch Leads Nohla’s $45M Series B” ). Nohla’s lead candidate, dilanubicel (NLA101)...
...be used as a bridging product to support engraftment. Nohla Therapeutics Inc., Seattle, Wash. Jaime De Leon Dilanubicel (NLA101) Nohla...
BioCentury | May 18, 2018
Financial News

Arch leads Nohla's $45M series B

...and previous investors 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners. Nohla’s lead candidate, dilanubicel (NLA101)...
...WuXi AppTec Co. Ltd. (Shanghai:603259) with which Nohla partnered in March for manufacturing of dilanubicel. Dilanubicel...
...by Arch (see BioCentury Extra, Nov. 29, 2016) . Nohla Therapeutics Inc., Seattle, Wash. Jaime De Leon Dilanubicel (NLA101) 5AM...
BioCentury | May 15, 2018
Financial News

Arch leads Nohla's $45M series B

...and previous investors 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners. Nohla’s lead candidate, dilanubicel (NLA101)...
...WuXi AppTec Co. Ltd. (Shanghai:603259) with which Nohla partnered in March for manufacturing of dilanubicel. Dilanubicel...
...BioCentury Extra, Nov. 29, 2016) . Jaime De Leon NLA101 5AM Ventures Alexandria Venture Investments Arch Venture Partners Celgene Corp. Nohla Therapeutics Inc. dilanubicel...
BioCentury | Nov 30, 2016
Financial News

Nohla raises $43.5M series A round

Nohla Therapeutics Inc. (Seattle, Wash.) raised $43.5 million in a series A round led by new investor Arch Venture Partners . New investor 5AM Ventures and existing investor Jagen Group also participated. Nohla’s lead programs, NLA-101...
Items per page:
1 - 5 of 5